观点医药

We ignore the disaster in the antibiotics market at our peril
救一救抗生素研发公司!


法拉尔:为了抗击超级细菌,我们需要新型抗生素。问题在于市场对这些新药需求不大,使制药公司难以生存下去。

Achaogen is not a company most people have heard of. It is not a household name, barely has an international presence and most of us have never used one of its products. The few who have probably don’t know the company either, even if its product saved their life. And yet its recently announced bankruptcy is one of the most significant — and worrying — corporate failures of this decade.

Achaogen是一家多数人没有听说过的公司。它并非家喻户晓,在海外没什么业务,而且我们多数人从未使用过它的产品。而使用过它的产品的少数人很可能也不了解这家公司,尽管其产品挽救过他们的生命。然而,最近,该公司宣布破产,这是本10年意义最为重大(而且最令人担忧)的公司破产事件之一。

您已阅读9%(529字),剩余91%(5674字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×